title: Emerging target-based paradigms to prevent and treat migraine.
abstract: Migraine is a primary brain disorder resulting from altered modulation of normal sensory stimuli and trigeminal nerve dysfunction. The second edition of the International Classification of Headache Disorders (ICHD-2) defines seven subtypes of migraine. Migraine treatment can be acute or preventive. New targeted therapies include 5-HT(1F) receptor agonists, calcitonin gene-related peptide (CGRP) antagonists, nitric oxide synthetase inhibitors, and ion channel antagonists. A recent development is the creation of antibodies to CGRP and its receptor for migraine prevention.
authors.affiliation: Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. stephen.silberstein@jefferson.edu
authors.forename: S D
authors.initials: SD
authors.lastname: Silberstein
mesh_terms: D000818:Animals; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D006801:Humans; D008881:Migraine Disorders / Q000145:classification / Q000188:drug therapy* / Q000517:prevention & control*; D018015:Receptors, Calcitonin Gene-Related Peptide / Q000502:physiology; D011985:Receptors, Serotonin / Q000502:physiology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D014276:Trigeminal Nerve / Q000187:drug effects / Q000502:physiology; D000096642:Receptor, Serotonin, 5-HT1F
chemical_list: D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D018015:Receptors, Calcitonin Gene-Related Peptide; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D000096642:Receptor, Serotonin, 5-HT1F